HDL3 (Hereditary Dementia Locus 3) is a condition with relevance to the neurodegenerative disease landscape. This page covers its molecular basis, clinical features, genetic associations, and connections to broader neurodegeneration research.
Hereditary Dementia Locus 3 (HDL3), also known as familial prion disease with chorea, is an extremely rare autosomal dominant neurodegenerative disorder characterized by progressive dementia, choreiform movements (involuntary dance-like movements), and psychiatric symptoms. It is caused by mutations in the prion protein gene (PRNP) and represents a distinct phenotypic variant of genetic prion disease.
- Extremely rare: Only a few families reported worldwide
- Inheritance: Autosomal dominant
- Age of onset: Variable, typically in adulthood (30-60 years)
- Gender: Equal distribution between males and females
- First described: 1996 by a German research group
¶ Genetics and Molecular Biology
HDL3 is caused by mutations in the PRNP gene located on chromosome 20p13, which encodes the cellular prion protein (PrP^C). Unlike other prion diseases caused by mutations in PRNP, HDL3 is characterized by specific mutations that produce a unique clinical phenotype dominated by chorea.
The following PRNP mutations have been associated with HDL3:
- P102L (proline to leucine at position 102) — Most commonly associated
- A117V (alanine to valine at position 117)
- Octapeptide repeat insertions — Variable number of repeats
These mutations alter the conformational conversion of the normal prion protein (PrP^C) to the pathogenic isoform (PrP^Sc), leading to neurodegeneration through mechanisms distinct from classic Creutzfeldt-Jakob Disease.
- Prion protein misfolding — Mutant PrP^C converts to PrP^Sc
- Neurotoxicity — Gain-of-function mechanism
- Synaptic loss — Particularly in striatal neurons
- Neuronal death — Progressive neurodegeneration
- Gliosis — Reactive astrocytosis and microgliosis
- Prion protein deposition — Patchy, synaptic-type deposits
- Spongiform changes — Vacuolation of neuropil (less prominent than CJD)
- Neuronal loss — Particularly in striatum and cortex
- Astrocytosis — Reactive glial responses
- Cerebellar involvement — Purkinje cell loss in some cases
- Basal ganglia — Caudate nucleus and putamen (striatum) — primary site of pathology, explaining chorea
- Cerebral cortex — Frontal and temporal lobes
- Hippocampus — Variable involvement
- Cerebellum — Less prominently affected than in classic CJD
- Thalamus — May show involvement
| Feature |
HDL3 |
Classic CJD |
Huntington's Disease |
| Primary symptom |
Chorea, dementia |
Rapid dementia, ataxia |
Chorea, behavioral changes |
| Disease course |
Variable (5-15 years) |
Rapid (weeks-months) |
Progressive (15-20 years) |
| PrP^Sc type |
Type 1 or 2 |
Type 1 or 2 |
Not applicable |
| EEG findings |
May be normal |
Typical periodic complexes |
Normal |
| MRI findings |
Basal ganglia abnormalities |
Cortical ribboning, cortical atrophy |
Caudate atrophy |
- Progressive chorea — Involuntary, irregular, jerky movements
- Initially: Mild, involving face and extremities
- Progresses: To severe, disabling movements
- Ataxia component — Gait instability develops
- Dyskinesias — May include dystonia and myoclonus
- Progressive dementia — Global cognitive impairment
- Memory deficits — Early and prominent
- Executive dysfunction — Planning, reasoning difficulties
- Language problems — Word-finding difficulties, eventual muteness
- Personality changes — Apathy, disinhibition
- Depression — Common early feature
- Anxiety — Generalized anxiety disorder
- Psychosis — Delusions and hallucinations in some cases
- Behavioral changes — Irritability, aggression
| Stage |
Duration |
Features |
| Early |
1-3 years |
Mild chorea, personality changes, subtle cognitive deficits |
| Intermediate |
3-7 years |
Progressive chorea, obvious dementia, psychiatric symptoms |
| Late |
7-15 years |
Severe movement disorder, profound dementia, immobility |
- Myoclonus — May develop later in disease course
- Seizures — Occur in some patients
- Pyramidal signs — Hyperreflexia, spasticity in later stages
- Pseudobulbar signs — Dysphagia, dysarthria
HDL3 should be suspected in patients presenting with:
- Autosomal dominant family history of neurodegenerative disease
- Progressive chorea beginning in adulthood
- Progressive dementia
- Psychiatric symptoms
- Absence of typical CJD features (rapid progression, characteristic EEG)
- PRNP sequencing — Identifies pathogenic mutations
- Codon 129 polymorphism — May influence phenotype
- Family screening — At-risk relatives
MRI Brain:
- T2/FLAIR hyperintensities in basal ganglia (caudate, putamen)
- Cortical atrophy, particularly frontal and temporal
- Cerebellar atrophy in some cases
- Unlike CJD: no characteristic cortical ribboning
PET/SPECT:
- Reduced glucose metabolism in striatum
- Dopaminergic deficit in basal ganglia
- 14-3-3 protein: May be positive or negative (less reliable than in CJD)
- Tau protein: Elevated in some cases
- PrP^Sc detection: Western blot may be positive
- Typically normal or shows nonspecific slowing
- No periodic sharp wave complexes (distinguishes from CJD)
- Huntington's disease and other Huntington-like disorders
- Other genetic prion diseases ( familial CJD, GSS)
- Wilson's disease
- Neuroacanthocytosis syndromes
- Spinocerebellar ataxias
- Frontotemporal dementia with movement disorder
Currently, no disease-modifying therapies exist specifically for HDL3. Treatment approaches being investigated include:
- Antisense oligonucleotides (ASOs) — Targeting PRNP expression
- Prion protein antibodies — Immunotherapeutic approaches
- Small molecule inhibitors — Of prion protein conversion
- Tetrabenazine — Reduces chorea through dopamine depletion
- Deutetrabenazine — Similar efficacy with better tolerability
- Valbenazine — VMAT2 inhibitor
- Antipsychotics — Haloperidol, olanzapine for severe chorea
- Benzodiazepines — For anxiety and myoclonus
- SSRIs — For depression and anxiety
- Antipsychotics — For psychosis and severe behavioral changes
- Mood stabilizers — For mood lability
- Physical therapy — Maintain mobility, prevent contractures
- Occupational therapy — Adaptive strategies for daily activities
- Speech therapy — For dysarthria and swallowing difficulties
- Nutritional support — Maintenance of adequate nutrition
- Psychological support — For patient and family
- Disease duration: 5-15 years from symptom onset
- Cause of death: Complications of neurodegeneration (aspiration pneumonia, infections, cachexia)
- Age of death: Typically 40-70 years
- Prognostic factors: Earlier onset may correlate with more rapid progression
- Transgenic mouse models — Expressing HDL3-associated mutations
- Knock-in models — Containing human PRNP mutations
- Used for: Understanding pathogenesis and testing therapeutic interventions
- Blood and CSF prion protein aggregates
- Neurofilament light chain (NfL) as neurodegeneration marker
- Neuroimaging biomarkers for disease progression
- ASO therapies targeting PRNP mRNA
- Antibody-based immunotherapies
- Small molecule stabilizers of PrP^C
- Gene therapy approaches
- Understanding disease heterogeneity
- Identifying prognostic biomarkers
- Developing clinical outcome measures
This section needs to be populated with recent publications.
- Genetic studies of the HDL3 locus
- Biomarker development for hereditary dementia
- Therapeutic target identification